Abbonarsi

An extracellular matrix-based signature associated with immune microenvironment predicts the prognosis of patients with hepatocellular carcinoma - 28/05/22

Doi : 10.1016/j.clinre.2022.101877 
Xinyun Zhang a, b, c, d, 1, Mengmeng Jiang a, b, c, d, 1, Xihao Zhang e, 1, Jinliang Zhang e, Hongxing Guo f, , Chenxuan Wu a, b, c, d,
a Department of Medical Oncology, The Third Central Hospital of Tianjin, China 
b Artificial Cell Engineering Technology Research Center, Tianjin, China 
c Tianjin Institute of Hepatobiliary Disease, Tianjin, China 
d Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases 
e Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Department of Hepatobiliary Surgery, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer 
f Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, The Third Central Hospital of Tianjin, China 

Corresponding authors at: Department of Medical Oncology, The Third Central Hospital of Tianjin, China; Artificial Cell Engineering Technology Research Center, Tianjin, China, Tianjin Institute of Hepatobiliary Disease, Tianjin, China, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases.Department of medical oncologyThe Third Central Hospital of TianjinArtificial Cell Engineering Technology Research Center, Tianjin, China, Tianjin Institute of Hepatobiliary Disease, Tianjin, China, Tianjin Key Laboratory of Extracorporeal Life Support for Critical DiseasesChina

Highlights

A series of investigations led us to identify 13 ECM-related genes which we utilized to construct a prognostic signature with a larger area under the curve of 0.808.
This ECM-related signature can be utilized as independent predictor of survival in HCC.
Low-risk patients stratified by the final model presented higher sensitivity to 8 targeted drugs (especially sorafenib) and 2 common chemo-drugs.
ECM-associated genes can play a crucial role in tumors development through immune system and that individuals at high risk with HCC can benefit from immunotherapy.
TGF-β pathway act as an important bridge between ECM remodeling procedures and TME of HCC and are worthy of further study.
This signature will assist patients of HCC and give new insights into the underlying processes of the disease.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Objective

Increased data showed that genes related to extracellular matrix (ECM) are important to hepatocellular carcinoma (HCC) development. In contrast, no research was carried out that proposed that ECM-related genes should be reliable prognostic signature.

Methods

This study used data from The Cancer Genome Atlas along with The International Cancer Genome Consortium to gather ECM-related gene expression as well as clinical information related to the extracellular matrix. The least absolute shrinkage, Cox analysis, along with selection operator Cox regression and random forest have been utilized for establishing an ECM-related prognostic models.

Results

A series of investigations led us to identify 13 ECMs which we utilized to construct a prognostic signature with a larger area under the curve of 0.808. HCC patients have been categorized into 2 main groups based on the risk score formula: low risk along with high risk. The findings of the Kaplan-Meier curve revealed that there had been a statistically significant difference between these two groups. Our ECM-related signature can be utilized as independent predictor of survival in HCC. Low-risk patients stratified by the final model presented higher sensitivity to 8 targeted drugs (especially sorafenib) and 2 common chemo-drugs. Our gene set enrichment analysis outcomes recommended that high-risk group have been enriched in ECM, tumorigenesis, as well as immune-related pathways. Immune cell analysis showed that high-risk group had lower cell fraction of CD8+ T cells, Macrophages M1, B naïve cells, memory resting CD4+ T cells, Monocytes, resting Dendritic cells and activated Mast cells, along with higher PD-1 and CTLA4 expression levels as compared to low-risk group.

Conclusion

Our identified ECM-related signature can also give new insight into underlying mechanisms along with therapeutic strategies in order to treat HCC.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Hepatocellular carcinoma, Extracellular matrix, CIBERSORT, Prognosis, Tumor microenvironment

Abbreviations : AUC, CTLs, DAVID, ECM, GO, GSEA, ICGC, KEGG, KM, OS, ROC, TCGA, TME, TIDE, TAMs


Mappa


© 2022  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 46 - N° 4

Articolo 101877- Aprile 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Validation of EncephalApp_Stroop as screening tool for the detection of minimal hepatic encephalopathy in German patients with liver cirrhosis
  • Leonard Kaps, Katharina Hildebrand, Michael Nagel, Maurice Michel, Wolfgang Maximilian Kremer, Max Hilscher, Peter R. Galle, Jörn M. Schattenberg, Marcus-Alexander Wörns, Christian Labenz
| Articolo seguente Articolo seguente
  • The effectiveness of radiofrequency ablation for patients with BCLC B1 stage hepatocellular carcinoma downgraded by transarterial chemoembolization
  • Lu Li, Yujing Xin, Xinyuan Zhang, Yi Chen, Yi Yang, Xiang Zhou, Feng Ye

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.